Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 01 November 2017 | By Zachary Brennan
The total number of deals in which brand name drugmakers pay to delay the entry of generic competitors continues to decline, and only 5 of the 170 final settlements in FY 2015 included compensation to the generic and a restriction on generic entry, the Federal Trade Commission (FTC) said in a report released Wednesday.
FY 2015 is the second complete year of filings since the Supreme Court decided FTC v. Actavis, Inc. in June 2013, when it found that a branded drug manufacturer’s reverse payment to a generic competitor to settle patent litigation can violate the antitrust laws. The decline in FY 2015 follows a similar decline revealed in an FTC report from last year.
"Consistent with FY 2014, the number of settlements potentially involving pay for delay continues to decrease significantly in the wake of the Actavis decision, even though the total number of settlements filed with the FTC has increased," the report said.
In FY 2015, the total number of final settlements was 170, which compares with 140 in FY 2012, 145 in FY 2013 and 160 in FY 2014. However, the number of potential pay-for-delay agreements in FY 2015 declined to 14, from a high of 40 pay-for-delay settlements in FY 2012.
Of those 14, 10 included compensation solely in the form of a cash payment for litigation fees (one of which included a cash payment of more than $7 million), while the other four involved compensation in the form of a brand manufacturer’s promise not to market an authorized generic in competition with the generic manufacturer for a period.
Ten additional final settlements are categorized by FTC as containing "possible compensation" because it is not clear if certain provisions in the deals amount to what should be considered compensation to the generic patent challenger.
"For example, an agreement containing a declining royalty structure, in which the generic’s obligation to pay royalties is reduced or eliminated if a brand launches an authorized generic product, may achieve the same effect as an explicit no-AG commitment," the report said.
In addition, 126 of the 170 final settlements restricted the generic manufacturer’s ability to market its product but did not include explicit or possible compensation.
FTC Report
Tags: pay-for-delay deals, generic delays
Regulatory Focus newsletters
All the biggest regulatory news and happenings.